Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis. (6th June 2020)

• Record Type: Journal Article
• Authors: Kloprogge, Frank; Mwandumba, Henry C; Banda, Gertrude; Kamdolozi, Mercy; Shani, Doris; Corbett, Elizabeth L; Kontogianni, Nadia; Ward, Steve; Khoo, Saye H; Davies, Geraint R; Sloan, Derek J
• Is Part Of: Open forum infectious diseases. Volume 7:Number 7(2020)
• Publication Date: 2020-06-06
• Subjects: outcome -- pharmacokinetics -- pharmacodynamics -- standard treatment -- tuberculosis; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa218
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: This study aims to explore relationships between baseline demographic covariates, plasma antibiotic exposure, sputum bacillary load, and clinical outcome data to help improve future tuberculosis (TB) treatment response predictions. Methods: Data were available from a longitudinal cohort study in Malawian drug-sensitive TB patients on standard therapy, including steady-state plasma antibiotic exposure (154 patients), sputum bacillary load (102 patients), final outcome (95 patients), and clinical details. Population pharmacokinetic and pharmacokinetic-pharmacodynamic models were developed in the software package NONMEM. Outcome data were analyzed using univariate logistic regression and Cox proportional hazard models in R, a free software for statistical computing. Results: Higher isoniazid exposure correlated with increased bacillary killing in sputum ( P < .01). Bacillary killing in sputum remained fast, with later progression to biphasic decline, in patients with higher rifampicin area under the curve (AUC)0-24 ( P < . 01). Serial sputum colony counting negativity at month 2 ( P < . 05), isoniazid C MAX ( P < .05), isoniazid C MAX /minimum inhibitory concentration ([MIC] P < . 01), and isoniazid AUC0-24 /MIC ( P < . 01) correlated with treatment success but not with remaining free of TB. Slower bacillary killing ( P < . 05) and earlier progression to biphasic bacillary decline ( P < . 01) both correlate with treatment failure. Posttreatment recurrence only correlated with slower bacillary killing ( P < . 05). Conclusions: Patterns of early bacillary clearance matter. Static measurements such as month 2 sputum conversion and pharmacokinetic parameters such as C MAX /MIC and AUC0-24 /MIC were predictive of treatment failure, but modeling of quantitative longitudinal data was required to assess the risk of recurrence. Pooled individual patient data analyses from larger datasets are needed to confirm these findings. Abstract : Systemic exposure to isoniazid and rifampicin correlates with bacillary clearance from sputum and bacillary clearance from sputum correlates with tuberculosis treatment outcome. These findings show the potential of longitudinal PKPD biomarkers for trial design and clinical decision making.